Accounting policies (Details Narrative)
|
|
|
|
|
|
|
|
1 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
|
Apr. 03, 2023
$ / shares
shares
|
Mar. 27, 2023
$ / shares
shares
|
Nov. 30, 2022
$ / shares
|
Nov. 30, 2022
$ / shares
shares
|
Nov. 27, 2022
USD ($)
$ / shares
shares
|
Nov. 27, 2022
GBP (£)
shares
|
Aug. 09, 2022
USD ($)
$ / shares
shares
|
Jun. 08, 2022
USD ($)
shares
|
Jun. 08, 2022
GBP (£)
shares
|
Feb. 10, 2022
USD ($)
$ / shares
shares
|
Feb. 10, 2022
GBP (£)
|
Nov. 30, 2022
USD ($)
|
Nov. 30, 2022
GBP (£)
|
Jun. 30, 2022
USD ($)
|
Jun. 30, 2022
GBP (£)
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2022
GBP (£)
|
Feb. 28, 2022
USD ($)
|
Feb. 28, 2022
GBP (£)
|
Apr. 30, 2021
USD ($)
|
Jun. 30, 2022
GBP (£)
|
Jun. 30, 2021
GBP (£)
|
Dec. 31, 2022
USD ($)
Integer
$ / shares
shares
|
Dec. 31, 2022
GBP (£)
Integer
|
Dec. 31, 2021
GBP (£)
shares
|
Dec. 31, 2020
GBP (£)
|
Apr. 24, 2023
USD ($)
|
Apr. 24, 2023
GBP (£)
|
Dec. 31, 2022
GBP (£)
shares
|
Nov. 24, 2022
shares
|
Nov. 15, 2022
shares
|
Aug. 09, 2022
GBP (£)
shares
|
Aug. 08, 2022
shares
|
Feb. 10, 2022
GBP (£)
shares
|
Jan. 10, 2022
shares
|
Aug. 25, 2020
shares
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
11,678
|
|
|
63,280
|
|
|
|
|
|
|
|
|
|
|
|
|
1,744,913
|
[1] |
|
390,952
|
[1] |
|
|
|
1,744,913
|
[1] |
3
|
21
|
11,678
|
|
63,280
|
|
15,891
|
Purchase of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,352
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
|
|
$ 0.50
|
|
|
$ 212.50
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 212.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative co-development agreements | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
£ 73,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retained earnings | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
£ 33,700,000
|
|
|
|
|
|
£ 33,700,000
|
|
|
|
|
£ 33,465,282
|
|
|
|
|
£ 33,731,738
|
|
|
|
|
|
|
|
|
Other inflows (outflows) of cash, classified as operating activities | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit (loss) | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,400,000
|
£ 13,600,000
|
|
|
£ (1,389,706)
|
£ (13,575,925)
|
|
£ (5,457,916)
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,800,000
|
|
|
|
|
|
4,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets excluding convertible loan notes | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,400,000
|
|
|
|
|
|
7,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilitites excluding convertible loan notes | £ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500,000
|
|
|
|
|
|
£ 2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from initial public offering |
|
|
|
|
|
|
|
|
|
|
|
$ 7,400,000
|
£ 6,200,000
|
$ 4,600,000
|
3,700,000
|
$ 5,500,000
|
£ 4,400,000
|
$ 17,500,000
|
£ 12,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commissions, costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
$ 6,600,000
|
£ 5,500,000
|
$ 3,800,000
|
£ 3,000,000.0
|
$ 4,600,000
|
£ 3,700,000
|
$ 14,500,000
|
£ 10,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of operating segments | Integer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage for income tax losses for cash rebate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33.35%
|
|
|
|
|
|
|
|
33.35%
|
|
|
|
|
|
|
|
|
License useful life |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software is amortized, on a straight-line basis, over the life of the relevant license (3 to 4 years).
|
|
Software is amortized, on a straight-line basis, over the life of the relevant license (3 to 4 years).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible loan note instrument | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20,000,000.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes and debentures issued |
|
|
|
|
|
|
$ 800,000
|
|
|
$ 13,447,012
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 14,228,245
|
|
|
|
|
|
|
|
£ 10,506,174
|
|
|
|
£ 600,000
|
|
£ 9,861,405
|
|
|
Repayments of subordinated liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,195,765
|
|
£ 2,632,324
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to subscribe |
|
|
|
|
|
|
11,678
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise price | $ / shares |
|
|
|
|
|
|
|
|
|
$ 4.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patent [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization methods and useful lives |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16 years
|
|
16 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licenses [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization methods and useful lives |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 years
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonadjusting event [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
$ 5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash on hand |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6,100,000
|
£ 4,900,000
|
|
|
|
|
|
|
|
|
|
Top of range [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
|
|
$ 25.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bottom of range [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
|
|
10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price | $ / shares |
|
|
|
|
|
|
$ 0.20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial offering public [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,693
|
|
|
|
|
|
|
|
24,693
|
|
|
|
|
|
|
24,693
|
|
Warrant reserve [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
126,560
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126,560
|
|
|
Nominal value per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A warrant [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of warrants |
|
|
|
|
$ 7,400,000
|
£ 6,073,376
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
$ 5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series B warrant [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
$ 5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prefunded warrant [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
|
$ 4.999
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prefunded warrant [member] | Nonadjusting event [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
3,676
|
230,000
|
230,000
|
63,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,676
|
|
63,280
|
|
|
Proceeds from issue of ordinary shares | £ |
|
|
|
|
|
|
|
|
|
|
£ 31,640
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
|
|
|
126,560
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126,560
|
|
|
Proceeds from exercise of warrants |
|
|
|
|
|
|
|
|
|
$ 13,447,012
|
9,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Funding costs |
|
|
|
|
|
|
|
|
|
$ 3,000,000.0
|
2,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of options |
|
|
|
|
|
|
|
$ 4,600,000
|
£ 3,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Offering expenses before deductions |
|
|
|
|
|
|
|
$ 780,000
|
£ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
|
|
2,800,000
|
155,000
|
155,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Nonadjusting event [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
215,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
$ 1.75
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Initial offering public [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
82,353
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,353
|
|
|
Proceeds from issue of ordinary shares | £ |
|
|
|
|
|
|
|
|
|
|
41,176
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
|
|
|
189,412
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
189,412
|
|
|
Proceeds from exercise of warrants |
|
|
|
|
|
|
|
|
|
$ 17,500,000
|
£ 12,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Warrant reserve [member] | Top of range [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
|
|
|
1,315,000
|
1,315,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Warrant reserve [member] | Top of range [member] | Nonadjusting event [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
3,222,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Series A warrant [member] | Top of range [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
|
|
|
1,470,000
|
1,470,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Series B warrant [member] | Top of range [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share purchased |
|
|
|
|
1,470,000
|
1,470,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
American depositary shares [member] | Prefunded warrant [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price | $ / shares |
|
|
|
$ 5.00
|
$ 5.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary share [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
63,280
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,280
|
|
|
Ordinary share [member] | Initial offering public [member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IfrsStatementLineItems [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued |
|
|
|
|
|
|
|
|
|
82,353
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,353
|
|
|
|
|